What is the roadmap for improving musculoskeletal health in London?
Personal view from Ian Bernstein, Clinical Director for Musculoskeletal Health, NHS England and NHS Improvement, London Region.
The Best MSK Health collaborative at NHS England brings together providers and people with lived experience to “enable best MSK health for all”. [1] The programme formally launched in February 2021 as we were riding the second COVID wave; and the timing is significant. We have known for many years that musculoskeletal problems are the largest cause of years lived with a disability in the UK.…
Read more of this article
BestMSK Health Collaborative Update and Futures Launch, 
by Sue Brown, CEO ARMA 
ARMA’s first ever online multi-disciplinary conference was a great end to a difficult year. We wanted to bring together the whole range of stakeholders from across MSK health, including policy makers and people living with MSK conditions to talk about how we can do things differently and work together.
Last month’s newsletter included a blog about how NHS England/Improvement is working in partnership with people with lived experience of MSK conditions to “co-produce” work on MSK services. In September, over fifty people joined our tweet chat on co-production. In the course of an hour, professionals and people with MSK conditions engaged in lively discussion and debate about what helps coproduction, what gets in the way and good examples in practice. A 
The NHS Change Challenge used crowdsourcing to identify almost 200 initiatives introduced during lockdown which proved beneficial. The project is now working to write these up in more detail so that we can publish them back onto the site for further comments and discussion. Due to the overwhelming responses received, the focus initially is on writing up the highest-scoring ideas based on impact and feasibility within each challenge area. 
by Greta McLachlan, Fellow at the Strategic planning and development cell, NHS England and Improvement, part of the Change Challenge Collaborative.